Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19

Elkodous, M. Abd; Olojede, Samuel Oluwaseun; Morsi, Mahmoud; El-Sayyad, Gharieb S.

doi:10.1039/d1ra04835j

Cited by 36 publications

(19 citation statements)

References 179 publications

(237 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, liposomes, nanoemulsions, and patches based on the micro needle are being investigated in preclinical studies, which may be proven as viable alternatives to invasive techniques [119]. The lipidic nanoparticles have proven exceptional applications in delivering the mRNA vaccine for COVID-19 infection, as evident from Moderna and BioNTech/Pfizer [124]. Moreover, a novel silica nanoparticle, Nuvec ® , has the potential to be administered as a viral vector or as a delivery system for the transfer of genetic material into host cells [125].…”

Section: Drug Delivery Route and Delivery Systemsmentioning

confidence: 99%

Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena

Chavda

Bezbaruah

Athalye

et al. 2022

Viruses

View full text Add to dashboard Cite

The “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” is the third member of human coronavirus (CoV) that is held accountable for the current “coronavirus disease 2019 (COVID-19)” pandemic. In the past two decades, the world has witnessed the emergence of two other similar CoVs, namely SARS-CoV in 2002 and MERS-CoV in 2013. The extent of spread of these earlier versions was relatively low in comparison to SARS-CoV-2. Despite having numerous reports inclined towards the zoonotic origin of the virus, one cannot simply sideline the fact that no animal originated CoV is thus far identified that is considered similar to the initial edition of SARS-CoV-2; however, under-sampling of the diverse variety of coronaviruses remains a concern. Vaccines are proved to be an effective tool for bringing the end to such a devastating pandemic. Many vaccine platforms are explored for the same but in this review paper, we will discuss the potential of replicating viral vectors as vaccine carriers for SARS-CoV-2.

show abstract

Section: Drug Delivery Route and Delivery Systemsmentioning

confidence: 99%

Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena

Chavda

Bezbaruah

Athalye

et al. 2022

Viruses

View full text Add to dashboard Cite

show abstract

“…Non-pharmacological countermeasures should be considered as an important approach as many countries do not have adequate sources of medicines and vaccines to prevent SARS-CoV-2 infection. Since the most important way of transmission is through aerosol droplets, it is necessary to use a facemask in public places, take care of contaminated hands and follow the usual hygienic methods [ 34 ]. Pathogens such as SARS-CoV-2 can remain on inanimate surfaces for more than 9 days [ 35 ].…”

Section: Preventionmentioning

confidence: 99%

“… The most common nanomaterials in drug delivery applications and their preparation methods. Reproduced with permission from [ 34 ]. Copyright American Chemical Society,2020.…”

Section: Figurementioning

confidence: 99%

Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment

et al. 2022

View full text Add to dashboard Cite

Following the announcement of the outbreak of COVID-19 by the World Health Organization, unprecedented efforts were made by researchers around the world to combat the disease. So far, various methods have been developed to combat this “virus” nano enemy, in close collaboration with the clinical and scientific communities. Nanotechnology based on modifiable engineering materials and useful physicochemical properties has demonstrated several methods in the fight against SARS-CoV-2. Here, based on what has been clarified so far from the life cycle of SARS-CoV-2, through an interdisciplinary perspective based on computational science, engineering, pharmacology, medicine, biology, and virology, the role of nano-tools in the trio of prevention, diagnosis, and treatment is highlighted. The special properties of different nanomaterials have led to their widespread use in the development of personal protective equipment, anti-viral nano-coats, and disinfectants in the fight against SARS-CoV-2 out-body. The development of nano-based vaccines acts as a strong shield in-body. In addition, fast detection with high efficiency of SARS-CoV-2 by nanomaterial-based point-of-care devices is another nanotechnology capability. Finally, nanotechnology can play an effective role as an agents carrier, such as agents for blocking angiotensin-converting enzyme 2 (ACE2) receptors, gene editing agents, and therapeutic agents. As a general conclusion, it can be said that nanoparticles can be widely used in disinfection applications outside in vivo. However, in in vivo applications, although it has provided promising results, it still needs to be evaluated for possible unintended immunotoxicity. Reviews like these can be important documents for future unwanted pandemics.

show abstract

“…However, FPV is a hydrophobic molecule with low solubility in water (8.7 mg/mL) as well as a short half-life, leading to rapid renal clearance in its hydroxylated form [31]. Therefore, the use of a nanocarrier such as lipid-based nano-formulations, nano-emulsion, and polymeric nanoparticles (NPs) is a rational approach to overcome the abovementioned limitations of FPV [32][33][34]. In addition, the use of biodegradable polymers as nanocarriers has been recognized by the FDA to enhance the drugs' stability and solubility [35][36][37][38].…”

Section: Introductionmentioning

confidence: 99%

“…Chun et al demonstrated that the co-encapsulation of FPV and mir-323a into amphiphilic copolymersomes enhanced in vitro cellular uptake and consequently resulted in a synergistic effect in controlling H1NI virus infection [34]. In another study, FPV-loaded nano-emulsion was postulated to facilitate the binding to the virus RNA-dependent RNA polymerase, prevent the SARS-CoV-2 virus replication, and destroy the viral structure [33]. In addition, liposomes, polymeric NPs and micelles have been used in pulmonary inhalation routes to improve medication efficacy and target drug delivery [39][40][41][42][43][44][45].…”

Section: Introductionmentioning

confidence: 99%

Physicochemical Characteristics and In Vitro Toxicity/Anti-SARS-CoV-2 Activity of Favipiravir Solid Lipid Nanoparticles (SLNs)

Tulbah

Lee

2021

Pharmaceuticals

View full text Add to dashboard Cite

The rise of coronavirus (COVID-19) cases worldwide has driven the need to discover and develop novel therapeutics with superior efficacy to treat this disease. This study aims to develop an innovative aerosolized nano-formulation of favipiravir (FPV) as an anti-viral agent against coronavirus infection. The local delivery of FPV nanoparticles (NPs) via nebulization ensures that the drug can reach the site of infection, the lungs. Solid lipid NPs of favipiravir (FPV-SLNs) were formulated utilizing the hot-evaporation method. The physicochemical formulation properties were evaluated using dynamic light scattering (DLS), Fourier-transform infrared spectroscopy (FTIR), and differential scanning calorimetry (DSC). The aerosol formulation performance was evaluated using an Andersen Cascade Impactor (ACI) at a flow rate of 15 L/min. The FPV-SLN formulation’s in vitro anti-viral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was also evaluated using the SARS-CoV-2 pathogen (hCoV-19/Egypt/NRC-3/2020 isolate). The FPV-SLNs’ morphology was defined utilizing transmission electron microscopy, showing an irregular shape. By means of FPV-SLNs’ nebulization, a fine particle fraction of 60.2 ± 1.7% was produced with 60.2 ± 1.7%, and this finding suggests that FPV-SLNs were appropriate for inhalation drug delivery with a particle size of 537.6 ± 55.72 nm. Importantly, the FPV-SLNs showed anti-viral activity against SARS-CoV-2 with CC50 and IC50 values of 449.6 and 29.9 µg/mL, respectively. This study suggests that inhaled solid lipid NPs of favipiravir could potentially be used against coronavirus.

show abstract

Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19

Abstract: We propose a consideration of Avigan-loaded nano-emulsions as a promising nano-based delivery system for the treatment of COVID-19.

Cited by 36 publications

References 179 publications

Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena

Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena

Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment

Physicochemical Characteristics and In Vitro Toxicity/Anti-SARS-CoV-2 Activity of Favipiravir Solid Lipid Nanoparticles (SLNs)

Contact Info

Product

Resources

About